To examine whether beta-agonists were associated with increased risk of sudden death in patients using the inhaled form of the agent to relieve bronchospasm, Lemaitre et al looked at 454 patients with ...
A new analysis that compares two common inhalers for patients suffering from chronic obstructive pulmonary disease (COPD) finds that one reduces respiratory-related hospitalizations and respiratory ...
In patients with chronic obstructive pulmonary disease (COPD), new initiation of beta2-agonist therapy, such as short-acting beta2-agonists (SABA), long-acting beta2-agonists (LABA), or inhaled ...
A new analysis that compares two common inhalers for patients suffering from chronic obstructive pulmonary disease finds that one reduces respiratory-related hospitalizations and respiratory deaths, ...
HealthDay News — A combination drug therapy of long-acting beta agonists (LABAs) and inhaled corticosteroids appears to be the best treatment for older adults with chronic obstructive pulmonary ...
The FDA has finalized label revisions for both single ingredient and combination long-acting beta-agonist-containing respiratory medications for the treatment of asthma. This action follows the ...
WINSTON-SALEM, N.C. – New research at Wake Forest University School of Medicine suggests that certain inhaled asthma medications – as well as similar chemicals our bodies produce during times of high ...
Overuse of rescue medication among asthma patients is associated with increased exacerbations and higher total and asthma-related healthcare costs. Objective: To assess whether increased short-acting ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA ® (mometasone furoate and formoterol fumarate dihydrate) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback